Inke participates in the 10th Pulmonary Drug Delivery Conference

This month, Inke took part in the 10th edition of the Pulmonary Drug Delivery Conference, held in Istanbul. This key event brought together leading experts and innovators from across the globe to explore the latest developments in inhalation therapies — a field in which Inke has been deeply involved for more than 25 years.

Over the course of three intensive days, our team had the opportunity to engage in discussions and presentations that addressed both emerging trends and critical challenges shaping the future of pulmonary drug delivery. Among the key topics highlighted during the conference:

• Inhaled biologics and the advances in dry powder formulations, alongside the ongoing evolution of inhalation devices.

• Sustainability in inhalation therapies, particularly the transition to low-global-warming-potential (GWP) pressurised metered-dose inhalers (pMDIs), as environmental responsibility becomes an increasingly central priority.

• New approaches for orally-inhaled products, including the use of well-established APIs such as GLP-1 analogues.

• Important updates in regulatory frameworks, with focus on the latest guidelines from the EMA, Japan, and the upcoming frameworks for orally inhaled and nasal drug products (OINDPs).

As a long-standing partner in the respiratory health sector, Inke remains committed to supporting our customers with high-quality inhalation APIs, specialised micronisation technologies, and technical excellence that helps bring innovative therapies to market efficiently and safely.

We would like to extend our thanks to the speakers, organisers, and fellow attendees for the opportunity to share insights, exchange knowledge, and continue advancing together in the field of pulmonary drug delivery.